forked from TBfighters/tbfightersdotorg
-
Notifications
You must be signed in to change notification settings - Fork 0
/
johnson-secondary-patents.html
92 lines (91 loc) · 6.35 KB
/
johnson-secondary-patents.html
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
<!DOCTYPE html>
<html lang="en">
<head>
<!--Meta tags-->
<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta name="description"
content="Fighting for accessible tuberculosis testing and treatment to save over a million lives a year. Take action with us now." />
<meta name="robots" content="index, follow" />
<!--Open Graph Tags-->
<meta property="og:site_name" content="TBFighters" />
<meta property="og:url" content="https://tbfighters.org" />
<meta property="og:image" content="img/og-image.jpg" />
<meta property="og:type" content="website" />
<meta property="theme-color" content="#D7211E" />
<!-- Style Tags -->
<link rel="stylesheet" href="style.css" />
<link rel="stylesheet" href="libs/toastify/toastify.css">
<link rel="icon" type="image/x-icon" href="img/favicon.ico">
<script src="menu.js" defer></script>
<script src="libs/toastify/toastify.js"></script>
<!-- Variable Tags -->
<meta name="robots" content="noindex">
<meta property="og:title" content="Johnson & Johnson Commit to Non-Enforcement of Secondary Patents | TBFighters" />
<meta property="og:site_name" content="TBFighters: Danaher, it's Time for $5" />
<meta property="og:description" content="Fighting for accessible tuberculosis testing and treatment to save over a million lives a year. Take action with us now." />
<title>Johnson & Johnson Commit to Non-Enforcement of Secondary Patents | TBFighters</title>
</head>
<body class="news">
<!--BELOW THIS GETS COPIED TO ALL PAGES WHEN MENU CHANGES (CHANGE BODY CLASS TO PAGE NAME)-->
<header id="site-head"><a href="#main" class="skip">Skip to main content</a>
<div class="wrapper-head">
<h1 class="page-title">
<a href="index.html"><span class="black-highlight">TB</span>FIGHTERS</a>
</h1>
<a id="hamburger-button" href="#" title="menu"></a>
<nav class="site-menu">
<ul class="active">
<li><a href="about.html">About Us</a></li>
<li><a href="timeline.html">News & Timeline</a></li>
<li><a href="resources.html">Resources</a></li>
<li><a href="action.html">Take Action</a></li>
</ul>
</nav>
</div>
</header>
<!--ABOVE THIS GETS COPIED TO ALL PAGES MENU CHANGES-->
<main id="main">
<section class="container container-full">
<div class="wrapper-full">
<h1 class="break-anywhere">
Johnson & Johnson Commit to Non-Enforcement of Secondary Patents in low- and middle-income countries
</h1>
<p class="news-date"><em>October 3, 2023</em></p>
<p>
TBfighters around the world are thrilled at the <a href="https://www.jnj.com/johnson-johnson-confirms-intent-not-to-enforce-patents-for-sirturo-bedaquiline-for-the-treatment-of-multidrug-resistant-tuberculosis-in-134-low-and-middle-income-countries" target="_blank">news</a> that Johnson & Johnson will not enforce secondary patents for SIRTURO® (bedaquiline) in 134 low- and middle-income countries. This builds upon their agreement with the Stop TB Partnership/Global Drug Facility (GDF), which allowed for generic bedaquiline in 44 countries. Johnson & Johnson’s announcement means people with multidrug-resistant tuberculosis (MDR-TB) will be able to access a more affordable bedaquiline-containing treatment regimen regardless of their country’s eligibility or willingness to procure drugs through the GDF.
</p>
<p>
Ending secondary patent enforcement will expand access to generic bedaquiline for countries such as South Africa, Ukraine, and Belarus, all of whom have a high-burden of TB but were excluded from the agreement with the GDF, meaning that until now they faced the continuation of high prices for bedaquiline. This represents a deep commitment to global health from J&J. This change of approach will save many lives, and allow more to avoid life-changing treatment complications, and we are truly thankful.
</p>
<p>
We are very glad to have played a part in this change, building upon and amplifying years of work from TB advocates and organizations, such as <a href="https://msfaccess.org/msf-calls-commitment-pharma-corporation-jj-not-enforce-extended-patents-lifesaving-tb-drug-main" target="_blank">MSF (Doctors Without Borders)</a>, <a href="https://www.pih.org/article/pih-urges-further-steps-ensure-tb-drugs-available-all" target="_blank">Partners in Health</a>, the <a href="https://www.stoptb.org/news/stop-tbs-global-drug-facility-announces-historic-price-reductions-to-55-bedaquiline-life-saving" target="_blank">Stop TB Partnership</a>, the <a href="https://www.treatmentactiongroup.org/" target="_blank">Treatment Action Group</a>, the <a href="https://www.compcom.co.za/" target="_blank">South African Competition Commission</a>, who launched an investigation into J&J’s bedaquiline pricing, and all those involved in the recent UN High Level Meeting on Tuberculosis, including <a href="https://unitaid.org/" target="_blank">UNITAID</a>. We look forward to working in partnership for further progress. Together, we can end TB.
</p>
</div>
</section>
</main>
<footer class="site-foot">
<p class="socials-wrapper-centered">
<a href="https://x.com/tbfighters" target="_blank">
<img src="img/socials/twitter.svg" alt="Twitter" class="social-icon">
<img src="img/socials/twitter-hover.svg" alt="Twitter" class="social-icon-hover"></a>
<a href="https://www.instagram.com/tbfighters" target="_blank">
<img src="img/socials/insta.svg" alt="Instagram" class="social-icon">
<img src="img/socials/insta-hover.svg" alt="Instagram" class="social-icon-hover"></a>
<a href="https://www.youtube.com/@TB_Fighters" target="_blank"><img
src="img/socials/youtube.svg" alt="Youtube" class="social-icon"><img
src="img/socials/youtube-hover.svg" alt="Youtube" class="social-icon-hover"></a>
<a href="https://www.facebook.com/profile.php?id=61555332203505" target="_blank"><img
src="img/socials/facebook.svg" alt="Facebook" class="social-icon"><img
src="img/socials/facebook-hover.svg" alt="Facebook" class="social-icon-hover"></a>
</p>
<hr style="width: 10%; margin: 0 auto; margin-bottom: 4px;">
<p>
© The TBFighters Project | <a href="privacy.html" class="footer-link">Privacy Policy</a>
</p>
<p class="too-small">
We lead by following and we act with compassion. Get in touch: contact at tbfighters dot org
</p>
</footer>
</body>
</html>